Company Overview of Albert Einstein College of Medicine
Albert Einstein College of Medicine is an educational institution.
1300 Morris Park Avenue
Jack and Pearl Resnick Campus
Bronx, NY 10461
Founded in 1984
Key Executives for Albert Einstein College of Medicine
Professor and Chairman of the Department of Cardiothoracic Surgery
Compensation as of Fiscal Year 2015.
Albert Einstein College of Medicine Key Developments
Jiangsu Hengrui Medicine Announce Collaboration with Albert Einstein College of Medicine to Advance Cancer Research and Drug Discovery
Apr 25 16
Jiangsu Hengrui Medicine Co., Ltd. announced that they have entered into a research agreement with Albert Einstein College of Medicine (Einstein) to advance cancer treatment. The multi-year cancer research agreement brings together the scientific and clinical capabilities of Einstein and Jiangsu Hengrui Medicine to develop innovative cancer therapies. The immediate goal of this research is to discover new targets and develop therapies in oncology space.
Albert Einstein College of Medicine Wins $1,999,645 Federal Contract
Sep 26 15
Albert Einstein College of Medicine won a $1,999,645 federal contract from the U.S. Health and Human Services Department's National Institutes of Health, Rockville, Maryland, to conduct a definitive randomized clinical trial of carbon ion radiotherapy versus 3D conformal radiation therapy for locally and advanced unresectable pancreatic cancer.
Actinium Announces Collaboration with Albert Einstein College of Medicine on New Actinium Program
Oct 27 14
Actinium Pharmaceuticals, Inc. announced collaboration with Albert Einstein College of Medicine on New Actinium Program. The company and Albert Einstein College of Medicine of Yeshiva University started development of an antibody construct labeled with actinium-225 using a novel technology that potentially allows for the expansion of use of the Company's proprietary platform and enables further manufacturing improvements of alpha therapy technology based drug candidates. The first antibody to be labeled using the new technology has potential to be broadly used in the field of hematology/oncology. Preclinical studies of the new technology have demonstrated significant improvements in product's manufacturing while maintaining biological integrity and properties of labeled antibodies. In addition to making the manufacturing process more time and cost efficient, the new technology allows for a greater versatility in adjusting the final constructs to various clinical situations. Clinical trials of drug candidates based on alpha emitting isotopes have already demonstrated significant efficacy with minimal side effects in blood borne cancers, in metastases of solid cancers and in residual disease in solid cancers post-surgery.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create
or control the content. For inquiries, please contact Capital IQ directly by clicking
Most Searched Private Companies
Sponsored Financial Commentaries